William Blair Has Bearish Estimate for AXDX FY2024 Earnings

Accelerate Diagnostics, Inc. (NASDAQ:AXDXFree Report) – Stock analysts at William Blair cut their FY2024 earnings estimates for Accelerate Diagnostics in a research note issued to investors on Monday, November 11th. William Blair analyst A. Brackmann now anticipates that the medical research company will post earnings of ($2.30) per share for the year, down from their prior estimate of ($2.14). The consensus estimate for Accelerate Diagnostics’ current full-year earnings is ($2.14) per share. William Blair also issued estimates for Accelerate Diagnostics’ Q4 2024 earnings at ($0.50) EPS, Q1 2025 earnings at ($0.49) EPS, Q2 2025 earnings at ($0.49) EPS, Q3 2025 earnings at ($0.50) EPS, Q4 2025 earnings at ($0.52) EPS and FY2025 earnings at ($2.00) EPS.

Separately, StockNews.com upgraded shares of Accelerate Diagnostics from a “sell” rating to a “hold” rating in a research report on Thursday.

View Our Latest Analysis on Accelerate Diagnostics

Accelerate Diagnostics Stock Down 1.1 %

NASDAQ:AXDX opened at $1.87 on Thursday. The company has a market capitalization of $46.82 million, a PE ratio of -0.65 and a beta of 0.59. Accelerate Diagnostics has a 52-week low of $0.73 and a 52-week high of $5.78. The stock has a fifty day simple moving average of $1.77 and a 200-day simple moving average of $1.46.

Hedge Funds Weigh In On Accelerate Diagnostics

A hedge fund recently raised its stake in Accelerate Diagnostics stock. Griffin Asset Management Inc. increased its stake in shares of Accelerate Diagnostics, Inc. (NASDAQ:AXDXFree Report) by 1.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,380,654 shares of the medical research company’s stock after purchasing an additional 26,400 shares during the quarter. Griffin Asset Management Inc. owned approximately 6.26% of Accelerate Diagnostics worth $1,615,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 17.14% of the company’s stock.

About Accelerate Diagnostics

(Get Free Report)

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.

Featured Articles

Earnings History and Estimates for Accelerate Diagnostics (NASDAQ:AXDX)

Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.